NFCR Writer David Perry, Author at NFCR

NFCR Writer David Perry

Daniel Haber: Him & HER2

“HER2 is a gene that codes for a protein sitting on the cell surface and sending signals for the cell to grow and divide,” explains Dr. Daniel Haber, Director at Massachusetts General Hospital Cancer Center and Professor of Oncology at Harvard Medical School, about one of the biggest genetic discoveries…...

Read more

Wei Zhang: The Art of Precision

“The essence of precision medicine, in particular precision oncology, is to make cancer management more precise based on genomic mapping and molecular characterization of the unique tumors for each patient,” says Dr. Wei Zhang. “The cancer management that needs to be precision include diagnosis, prognosis, treatment plan, treatment monitoring, and…...

Read more

Breakthrough: Single-Cell Sequencing

Genomics, the branch of molecular biology concerned with the structure, function, evolution, and mapping of an individual’s genes, is already revolutionizing the way medicine treats cancer. Like many sciences, genomics has “niches;” single-cell genomics is a rapidly developing field, and current technologies can assay a single cell’s gene expression, DNA…...

Read more

Prostate Cancer Awareness Month: Signs, Symptoms and Treatments

Prostate cancer is, after skin cancer, the most common cancer among men and the second biggest cancer killer for men in the United States. It’s typically an older man’s cancer with approximately 60 percent diagnoses in men over 65, with the average age being 66. As cancers go, prostate cancer…...

Read more

Leukemia Drug Finds New Use

Approved by the FDA in 1993, the drug cladribine offered hope for the then-fatal blood cancer called hairy cell leukemia, or HCL, and was soon expanded as a therapy for multiple sclerosis. Developed by NFCR scientist Dr. Dennis Carson at the University of California, San Diego, cladribine acts like a…...

Read more

Genetic Cues to Ovarian Cancer Explored

September is Ovarian Cancer Awareness Month, highlighting a disease that kills nearly 15,000 women annually out of the 21,000 diagnosed. Relatively uncommon as cancers go, ovarian cancer nevertheless causes the most deaths from all gynecological cancers. Known as the “silent killer”, Ovarian Cancer presents no symptoms at all, or symptoms…...

Read more

The Hallmarks of Metastasis

It is the one word you do not want to hear in a cancer diagnosis: metastasis. It represents the figurative death-knell; once a cancer has spread to other parts of the body, survival rates plummet and what treatments do exist switch from curative to palliative. The dividing line metastatic cancer…...

Read more

New Combination Therapy Improves Pancreatic Cancer Survival

A new combination of two standing drugs and radiation therapy has the potential to revolutionize the treatment and care of pancreatic cancer, one of the most lethal diagnoses an oncologist can face with patients. Using data from studies by NFCR fellow Dr. Rakesh Jain, investigators at Massachusetts General Hospital used…...

Read more

Brian Leyland-Jones: Now Is the Time!

“This is the transformative time in oncology,” heralds Brian Leyland-Jones, M.B., B.S., Ph.D., and there is no spin doctoring in the statement by the member of the National Foundation for Cancer Research’s scientific advisory board. From genomics to targeted therapies to vaccinations, the last 40 years has seen more strides…...

Read more